๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

P889 NEW NUCLEOS(T)IDE ANALOGUE MONOPROPHYLAXIS AFTER HEPATITIS B IMMUNOGLOBULIN WITHDRAWAL IS SAFE AND EFFECTIVE AGAINST HEPATITIS B RECURRENCE AFTER LIVER TRANSPLANTATION

โœ Scribed by Cholongitas, E.; Goulis, J.; Antoniadis, N.; Fouzas, I.; Imvrios, G.; Vasiliadis, T.; Papanikolaou, V.; Akriviadis, E.

Book ID
122714045
Publisher
Elsevier Science
Year
2014
Tongue
English
Weight
79 KB
Volume
60
Category
Article
ISSN
0168-8278

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Hepatitis B immunoglobulin and/or nucleo
Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: A systematic review
โœ Evangelos Cholongitas; John Goulis; Evangelos Akriviadis; Geore V. Papatheodorid ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 395 KB

A combination of hepatitis B immunoglobulin (HBIG) and nucleos(t)ide analogues (NUCs) is currently recommended as prophylaxis against the recurrence of hepatitis B virus (HBV) after liver transplantation (LT), but the optimal protocol is a matter of controversy. The aim of this study was the identif

Low risk of hepatitis B virus recurrence
Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy
โœ Stephen N. Wong; Chi-Jen Chu; Chun-Tao Wai; Terese Howell; Charles Moore; Robert ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 103 KB

Hepatitis B virus (HBV) recurrence rates of 0-16% had been reported in patients maintained on nucleoside analogues (NA) after hepatitis B immunoglobulin (HBIG) discontinuation after orthotopic liver transplantation (OLT). However, follow-up in most studies was short. We aimed to determine the long-t